Peter Ellmark
11 – 20 of 57
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
- Contribution to journal › Article
-
Mark
Transcriptional profiling demonstrates altered characteristics of CD8 + cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia
- Contribution to journal › Article
- 2021
-
Mark
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
- Contribution to journal › Article
-
Mark
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
- Contribution to journal › Scientific review
-
Mark
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
- Contribution to journal › Article
- 2020
-
Mark
Transcriptomic profiling of T-cell populations in non-muscle invasive and muscle invasive bladder cancer.
(2020) The Society for Immunotherapy of Cancer's (SITC) 35th annual meeting In Journal for ImmunoTherapy of Cancer 8(Suppl. 3).
- Contribution to journal › Published meeting abstract
-
Mark
Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
- Contribution to journal › Article
- 2019
-
Mark
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
- Contribution to journal › Article
-
Mark
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
- Contribution to journal › Article
- 2018
-
Mark
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
- Contribution to journal › Article
